Literature DB >> 20425795

Differential expression of specific microRNA and their targets in acute myeloid leukemia.

Giuseppe Cammarata1, Luigi Augugliaro, Domenico Salemi, Cecilia Agueli, Maria La Rosa, Lea Dagnino, Gabriele Civiletto, Francesca Messana, Anna Marfia, Maria Grazia Bica, Lucia Cascio, Pietro Michele Floridia, Angelo M Mineo, Mario Russo, Francesco Fabbiano, Alessandra Santoro.   

Abstract

Acute myeloid leukemia (AML) the most common acute leukemia in adults is characterized by various cytogenetic and molecular abnormalities. However, the genetic etiology of the disease is not yet fully understood. MicroRNAs (miRNA) are small noncoding RNAs which regulate the expression of target mRNAs both at transcriptional and translational level. In recent years, miRNAs have been identified as a novel mechanism in gene regulation, which show variable expression during myeloid differentiation. We studied miRNA expression of leukemic blasts of 29 cases of newly diagnosed and genetically defined AML using quantitative reverse transcription polymerase chain reaction (RT-PCR) for 365 human miRNA. We showed that miRNA expression profiling reveals distinctive miRNA signatures that correlate with cytogenetic and molecular subtypes of AML. Specific miRNAs with consolidated role on cell proliferation and differentiation such as miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes. We observed a significant differentially expressed miRNA profile that characterizes two subgroups of AML with different mechanism of leukemogenesis: core binding factor (CBF) and cytogenetically normal AML with mutations in the genes of NPM1 and FLT3-ITD. We demonstrated, for the first time, the inverse correlation of expression levels between miRNA and their targets in specific AML genetic groups. We suggest that miRNA deregulation may act as complementary hit in the multisteps mechanism of leukemogenesis offering new therapeutic strategies. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20425795     DOI: 10.1002/ajh.21667

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  73 in total

1.  MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output.

Authors:  Ryan M O'Connell; Aadel A Chaudhuri; Dinesh S Rao; William S J Gibson; Alejandro B Balazs; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

2.  MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia.

Authors:  Yan Guo; Stephen A Strickland; Sanjay Mohan; Shaoying Li; Amma Bosompem; Kasey C Vickers; Shilin Zhao; Quanhu Sheng; Annette S Kim
Journal:  Leuk Lymphoma       Date:  2017-01-13

3.  Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.

Authors:  Chinavenmeni S Velu; Aditya Chaubey; James D Phelan; Shane R Horman; Mark Wunderlich; Monica L Guzman; Anil G Jegga; Nancy J Zeleznik-Le; Jianjun Chen; James C Mulloy; Jose A Cancelas; Craig T Jordan; Bruce J Aronow; Guido Marcucci; Balkrishen Bhat; Brian Gebelein; H Leighton Grimes
Journal:  J Clin Invest       Date:  2013-12-16       Impact factor: 14.808

Review 4.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

Review 5.  The prognostic and functional role of microRNAs in acute myeloid leukemia.

Authors:  Guido Marcucci; Krzysztof Mrózek; Michael D Radmacher; Ramiro Garzon; Clara D Bloomfield
Journal:  Blood       Date:  2010-11-02       Impact factor: 22.113

6.  MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.

Authors:  D-J Min; T Ezponda; M K Kim; C M Will; E Martinez-Garcia; R Popovic; V Basrur; K S Elenitoba-Johnson; J D Licht
Journal:  Leukemia       Date:  2012-09-13       Impact factor: 11.528

7.  miR-199b-5p directly targets PODXL and DDR1 and decreased levels of miR-199b-5p correlate with elevated expressions of PODXL and DDR1 in acute myeloid leukemia.

Authors:  Amanda J Favreau; Erin L Cross; Pradeep Sathyanarayana
Journal:  Am J Hematol       Date:  2012-02-28       Impact factor: 10.047

8.  MKL1 and MKL2 play redundant and crucial roles in megakaryocyte maturation and platelet formation.

Authors:  Elenoe C Smith; Jonathan N Thon; Matthew T Devine; Sharon Lin; Vincent P Schulz; Yanwen Guo; Stephanie A Massaro; Stephanie Halene; Patrick Gallagher; Joseph E Italiano; Diane S Krause
Journal:  Blood       Date:  2012-07-17       Impact factor: 22.113

9.  miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.

Authors:  Jared A Wallace; Dominique A Kagele; Anna M Eiring; Carissa N Kim; Ruozhen Hu; Marah C Runtsch; Margaret Alexander; Thomas B Huffaker; Soh-Hyun Lee; Ami B Patel; Timothy L Mosbruger; Warren P Voth; Dinesh S Rao; Rodney R Miles; June L Round; Michael W Deininger; Ryan M O'Connell
Journal:  Blood       Date:  2017-04-21       Impact factor: 22.113

10.  NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.

Authors:  D Gerloff; R Grundler; A A Wurm; D Bräuer-Hartmann; C Katzerke; J-U Hartmann; V Madan; C Müller-Tidow; J Duyster; D G Tenen; D Niederwieser; G Behre
Journal:  Leukemia       Date:  2014-08-05       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.